President & CEOOfficers of the CorporationBoard of TrusteesFoundation BoardLeadership CouncilAbout Joslin ResearchAdvocacy & Gov't AffairsHistory
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Make an AppointmentAdult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAfrican American ProgramsAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingHealthcare ProfessionalsCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Type 1 Diabetes Research

Joslin researchers spearhead the fight to predict, prevent, detect, treat and eventually cure the insulin-dependent form of diabetes that often strikes the young.

Retraining the Autoimmune System in Type 1 Diabetes

Research at Joslin seeks to sort out the diabolically complicated details of the autoimmune attack and to work toward steps that can be taken to stop it.

The Problem of Not Enough Beta Cells in Type 1 Diabetes

Joslin researchers lead in pursuing several strategies to replenish the insulin-producing beta cells destroyed in the disease.

Q&A | Thomas Serwold on Type 1 Diabetes and Autoimmunity

Thomas Serwold, Ph.D., who joined Joslin’s Immunobiology research section last year, talks about progress in understanding the attack that triggers type 1 diabetes.

Q&A | Howard Wolpert on CGM Research and the Artificial Pancreas

An expert on adopting technology for managing type 1 diabetes, Howard Wolpert, M.D., answers questions about his lab’s Continuous Glucose Monitoring (CGM) studies and the quest for an artificial pancreas.

Ultimate Diabetes Survivors, the Joslin 50-Year Medalists, Give Clues to Cures

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

Page last updated: July 26, 2014